Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AHT956 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| AHT956 | DRUG | - |
Inclusion Criteria: * Healthy male and female subjects age 18 to 45 years of age included, and in good health as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory tests at screening. * Vital signs must be within the following ranges: oral body ...
AHT956 is an investigational small molecule developed by Novartis AG. It has been studied in a Phase 1 clinical trial in healthy adult volunteers, and no therapeutic indication has been disclosed for the compound. It is not an approved medicine and remains in early clinical development.
AHT956 is being developed by Novartis AG, which trades under the ticker NVS. Novartis sponsored the Phase 1 study of the compound conducted in Switzerland. No partnership or licensing arrangement for AHT956 has been announced.
AHT956 is in Phase 1 development. One Phase 1 trial has been completed, and no active trials are currently listed. Because only early-stage testing has been conducted, AHT956 is investigational and has not been approved by the FDA or any other regulatory authority.
AHT956 has been evaluated in one completed Phase 1 trial, NCT00410228, titled "Study to Explore the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AHT956 in Healthy Subjects." The study enrolled 42 healthy adult volunteers in Switzerland and used a randomized, double-blind design.
The AHT956 Phase 1 trial, NCT00410228, was a randomized, double-blind study of oral AHT956 in 42 healthy volunteers aged 18 years and older in Switzerland. It assessed safety, tolerability, pharmacokinetics and pharmacodynamics. The study is listed as completed and enrolled healthy participants rather than patients with a specific disease.